Financial Review: Peak Bio (NASDAQ:PKBO) & ADMA Biologics (NASDAQ:ADMA)

Peak Bio (NASDAQ:PKBO) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Valuation and Earnings

This table compares Peak Bio and ADMA Biologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Bio	$370,000.00	11.25	-$12.83 million	N/A	N/A
ADMA Biologics	$330.24 million	13.88	-$28.24 million	($0.02)	-988.50

Peak Bio has higher earnings, but lower revenue than ADMA Biologics.

Insider and Institutional Ownership

75.7% of ADMA Biologics shares are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Peak Bio and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	-253.92%
ADMA Biologics	10.53%	38.79%	17.35%

Risk and Volatility

Peak Bio has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Peak Bio and ADMA Biologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Bio	0	0	0	0	N/A
ADMA Biologics	0	0	3	1	3.25

ADMA Biologics has a consensus target price of $15.50, suggesting a potential downside of 21.60%. Given ADMA Biologics’ higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Peak Bio.

Summary

ADMA Biologics beats Peak Bio on 10 of the 12 factors compared between the two stocks.

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.